Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$109.37M-32.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael E. Castagna
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 592
- Beta
- 1.10
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.52
Financials
Revenue
$109.37M-32.6%Net Income
$-19.03M-115.0%EBITDA
$12.94M-90.2%Free Cash Flow
$-23.45MEPS (diluted)
$-0.06-104.6%Shares Outstanding (diluted)
309.19M+220.2%Operating Expenses
$76.30MCash & Debt
$111.13MReturn of Capital
$0.00Revenue by Segment (annual)
$348.97MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $348.97M | $5.86M | $0.02 |
| 2024 | $285.50M | $27.59M | $0.10 |
| 2023 | $198.96M | $-11.94M | $-0.04 |
| 2022 | $99.77M | $-87.40M | $-0.44 |
| 2021 | $75.44M | $-80.93M | $-0.37 |
| 2020 | $65.14M | $-57.24M | $-0.26 |
| 2019 | $63.04M | $-51.90M | $-0.31 |
| 2018 | $27.86M | $-86.97M | $-0.60 |
| 2017 | $11.74M | $-117.33M | $-1.13 |
| 2016 | $174.76M | $125.66M | $1.37 |
| 2015 | $0.00 | $-368.44M | $-4.54 |
| 2014 | $0.00 | $-198.38M | $-2.57 |
| 2013 | $0.00 | $-191.49M | $-3.20 |
| 2012 | $35.0K | $-169.37M | $-4.68 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.03
- Implied price
- $0.51
- Return from $3.80
- -33.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.25 — -93.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -44.1% | -41.5% | -39.3% | -37.4% | -35.7% |
| 3.0% | -41.2% | -38.5% | -36.2% | -34.2% | -32.5% |
| 8.0% | -38.4% | -35.5% | -33.1% | -31.1% | -29.2% |
| 13.0% | -35.5% | -32.6% | -30.1% | -27.9% | -25.9% |
| 18.0% | -32.6% | -29.6% | -27.0% | -24.7% | -22.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
125+25.00%Social Signal Score
Mentions (5)
- Newsmarketbeat.com·18d ago·Positive
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
MannKind to Present at Upcoming Investor Conferences DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
View source ↗ - Newszacks.com·38d ago·Neutral
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
MannKind: New Approvals Majorly Increase MannKind's Prospects Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.08 per share
Typical surprise -47.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.06 vs $-0.01miss
- Wed, May 6$-0.05 vs $-0.02miss
- Thu, Feb 26$-0.05 vs $-0.01miss
- Wed, Nov 5$0.03 vs $0.01beat
- Wed, Aug 6$0.00 vs $0.04miss
- Thu, May 8$0.04 vs $0.03beat
Estimates and results for MNKD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MNKD officers and directors.
- Bought
- $259k
- Sold
- $2.2m
1 trade
11 trades
- Binder Steven B.sold
- Binder Steven B.sold
- Binder Steven B.sold
- Thomson Davidsold
- Binder Steven B.sold
- Binder Steven B.sold
- Thomson Davidsold
- Castagna Michaelbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MNKD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.